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Abstract
The reproducibility of assessing potential biomarkers is crucial for their implementation. ONEST (Observers Needed to 
Evaluate Subjective Tests) has been recently introduced as a new additive evaluation method for the assessment of reliability, 
by demonstrating how the number of observers impact on interobserver agreement. Oestrogen receptor (ER), progesterone 
receptor (PR), and Ki67 proliferation marker immunohistochemical stainings were assessed on 50 core needle biopsy and 50 
excision samples from breast cancers by 9 pathologists according to daily practice. ER and PR statuses based on the percent-
ages of stained nuclei were the most consistently assessed parameters (intraclass correlation coefficients, ICC 0.918–0.996), 
whereas Ki67 with 5 different theoretical or St Gallen Consensus Conference–proposed cut-off values demonstrated moderate 
to good reproducibility (ICC: 0.625–0.760). ONEST highlighted that consistent tests like ER and PR assessment needed 
only 2 or 3 observers for optimal evaluation of reproducibility, and the width between plots of the best and worst overall 
percent agreement values for 100 randomly selected permutations of observers was narrow. In contrast, with less consistently 
evaluated tests of Ki67 categorization, ONEST suggested at least 5 observers required for more trustful assessment of reli-
ability, and the bandwidth of the best and worst plots was wider (up to 34% difference between two observers). ONEST has 
additional value to traditional calculations of the interobserver agreement by not only highlighting the number of observers 
needed to trustfully evaluate reproducibility but also by highlighting the rate of agreement with an increasing number of 
observers and disagreement between the better and worse ratings.
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Introduction
Breast cancer is a heterogenous disease. This heterogeneity 
is reflected in the classifications of the disease along several 
parameters, e.g., histological type, imaging features, and 
several prognostic and/or predictive markers, some of which 
impact significantly on therapy.
Of the classifications, one of the most important is the 
segregation of carcinomas into oestrogen receptor (ER)–pos-
itive (ER+) and ER-negative (ER-) groups, of which only 
the first is likely to benefit from endocrine treatments. Cur-
rently, ER status is universally determined by immunohis-
tochemistry (IHC) and the judgement of what constitutes an 
ER+ and ER- status is somewhat arbitrary and may depend 
on a number of pre-analytical and analytical issues, which 
are attempted to be minimalized by regularly updated guide-
lines such as the American Society of Clinical Oncology 
(ASCO) recommendations [1]. ER positivity had often been 
defined by an inclusive cut-off value of 10% [2, 3], then 
1% [3]. At present, it is acknowledged that ER+ cancers 
with 1–10% ER expression may respond to endocrine treat-
ment, but their response might be below expectations, and 
 * Gábor Cserni 
 cserni@freemail.hu
1 TNG Technology Consulting GmbH, Budapest, Hungary
2 Department of Pathology, Bács-Kiskun County Teaching 
Hospital, Kecskemét, Hungary
3 Department of Pathology, University of Szeged, Szeged, 
Hungary




therefore, these tumours have been allocated to the category 
of low-ER-expressing carcinomas [1, 4]. Indeed, the level of 
ER expression reflects the degree of endocrine responsive-
ness as exemplified by the response to adjuvant tamoxifen 
therapy in the function of the Allred scores (derived sum of 
the intensity subscores 0–3 and semiquantitative percentage 
of positive cells subscores 0–5) [5]); the greater the score, 
the better the response [6].
Progesterone receptors (PR) also influence endocrine 
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Fig. 1  ONEST plots of ER (A), PR (B), and Ki67 (C) classifications 
into < 1%, 1–10%, and > 10% categories on CNB with all 100 random 
permutations of pathologists (A-B-C 1) and just the best and worst 
OPA values (A-B-C 2). Note: C2 demonstrates best that with the 
increasing number of pathologists, the OPA decreases till reaching 
a plateau with 4 pathologists. The classification can be characterized 
with the distance between the minimum and maximum OPA with 2 
pathologists (0.94–0.76 = 0.18), the number of pathologists required 
for reaching the plateau (4), the approximate value of the plateau 
(0.64), and the OPA for all pathologists (0.62). Categorizations with 
good reproducibility have a narrow gap (bandwidth) between the 
maximum and minimum values, reach the plateau with few patholo-
gists and have a high OPA with all pathologists (A1, A2). While A1, 
B1, and C1 demonstrate 100 OPAC each; A2, B2, and C2 show the 
minimum and maximum OPA values and do not necessarily overlap 
with an OPAC from the 100 permutations, but obviously overlap with 
an OPAC from all permutations. The worst scenario, i.e., the mini-
mum OPA values were selected to characterize the categorizations
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of the ER pathway [4], recently they have been proposed to 
be actively involved in this pathway [7]. The evaluation of 
PR and its interpretation is similar to that of ER, and the 
Allred scoring is also applicable.
Ki67 is a protein which is expressed in variable amounts 
through the cell cycle, except in the G0 phase, and is a pro-
liferation marker of prognostic significance [8]. Several cut-
offs have been suggested to divide ER+ tumours into the 
low proliferation good prognosis (luminal A-like) category 
and the more aggressive, more proliferative (luminal B-like) 
one [9–12]. Despite the accepted prognostic role, owing to 
concerns about standardization, Ki67 is not part of general 
recommendations, although it is part of the IHC4 prognostic 
classifier [13]. As an estimate of proliferative tumour cells, 
it is also part of Hungarian guidelines for assessing breast 
carcinomas [14].
ER, PR, and Ki67 assessment by microscopy requires 
the quantification of nuclei that stain with the relevant 
antibodies. The common method of doing this is by eye-
balling, i.e., having a look at the slide and estimating 
the amount of tumour cell staining. This may be tuned 
by estimating the area occupied by 100–200 cells, made 
more precise by counting 500–2000 cells [15], facilitating 
the count with an application [16, 17], or by using digi-
tal image analysis [18–20] or artificial intelligence [21]. 
Because of the costs and time required for the latter meth-
ods deemed more precise and reproducible, eyeballing is 
probably the most generally used method worldwide and 
is not obviously worse than some forms of digital image 
analysis [22].
Reproducibility issues have been analysed by multiple 
groups. In general, the interobserver agreement for ER and 
PR assessment for clinical management issues has been 
excellent for ER-negative cases and fair or good for strongly 
positive cases, with the worst consistency in allocating 
tumours to the moderate and low level of receptor positiv-
ity [23]. The interobserver consistency has most commonly 
been assessed by kappa statistics or intraclass correlation 
coefficients. We sought at investigating these predictive/
prognostic tests by ONEST (Observers Needed to Evaluate 
Subjective Tests) [24].
ONEST is a recently developed method to characterize 
how a subjective test requiring quantitative estimations of 
microscopic images can be reproduced by multiple observ-
ers. It has been created to analyse the performance of the 
atezolizumab related PD-L1 (programmed death-ligand 1) 
evaluation algorithm in breast cancer. More precisely, it was 
introduced to characterize how the estimation of the tumour 
area occupied by PD-L1 IHC stained immune cells being at 
least 1% (positive) or less (negative) could be reproduced by 
multiple observers. This PD-L1 assessment assay has been 
claimed to have 95% overall percent (proportion) agreement 
(OPA; i.e., the proportion of cases with full agreement on 
classification) on the basis of 2 observers [24], but empiri-
cism suggested that the diagnostic test was less reproducible. 
ONEST is based on plotting the OPAs (0–1; correspond-
ing to 0–100% agreement) against the increasing number 
of pathologists (observers) for 100 permutations randomly 
selected from all possible permutations of pathologists (i.e., 
the factorial product of the number of pathologists involved). 
Examples follow in the “Results” section, Fig. 1. Each plot-
ted OPA for a given permutation results in an OPA curve 
(OPAC), and the 100 OPACs represent the full ONEST plot. 
The resulting ONEST plots highlight the number of patholo-
gists where the OPA levels off, reaching a plateau. ONEST 
therefore suggests the number of pathologists required to 
reach this plateau (i.e., the number of observers to give 
adequate estimations of reproducibility); the plateauing 
value itself gives an estimate of overall agreement that can 
be expected. Finally, the graph also illustrates the OPA for 
all pathologists (the percentage of cases in which all raters 
agree) at the point to which all curves converge on the right 
side of the ONEST plot. It is also possible to visualize the 
greatest difference in agreement between two observers 
(wide versus narrow curve ranges). By applying ONEST to 
the PD-L1 algorithm tested, about 40% agreement plateau 
was reached with 8 observers [24]. Well reproducible tests 
have high values of OPA with low numbers of raters to reach 
the plateau and a small difference between the best and worst 
agreement of two raters.
This study was performed to evaluate the assessment of 
3 IHC based biomarkers with nuclear staining by means of 
ONEST. The aims were to test the applicability of the new 
method in reproducibility studies, to see how ONEST can 
contribute to visualize discrepancies in classifications and 
to compare the 3 similarly evaluated biomarkers in terms of 
reproducibility and conduct with ONEST.
Materials and methods
From the archives of the Bács-Kiskun County Teaching 
Hospital, 100 breast cancer cases with routine determina-
tion of ER, PR, and Ki67 were selected. The cases included 
50 core biopsy samples which were taken with a policy to 
obtain at least 3 cores by 14-G needle biopsy gun (CNB) 
and 50 samples from unrelated resected tumour specimens 
(EXC). These cases were relatively consecutive, but some 
ER-PR- cases were discarded to allow better variation of the 
ER and PR values.
The IHC was performed with monoclonal antibodies 
6F11 (Novocastra, Leica, Newcastle, UK) for ER, PgR312 
(Novocastra, Leica, Newcastle, UK) for PR, and MIB1 
(Dako-Agilent, Glostrup, Denmark) for Ki67. Participants 
were asked to report the percentage of cell staining for all 
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three IHC reactions, along with the average staining inten-
sity and Allred scores for ER and PR.
The ER and PR data were categorized as negative (< 1% 
staining), weekly positive (1–10%), and positive (> 10%). 
Mean intensity scores were given as nil (0), weak (1), 
medium (2), or strong (3). The Allred scores were catego-
rized into broader groups (0, 2 vs 3–4 vs 5–6 vs 7–8), fol-
lowing the European Working Group for Breast Screening 
Pathology earlier practice [23].
The Ki67 values were assessed following the Hungar-
ian breast pathology recommendations, which allow for 
eyeballing-based estimation of the Ki-67-labelling fraction 
with rounding to the closest 5%. Individual practice includes 
an estimation similar to ER and PR, but also more quanti-
tative estimations like delineation of groups of about 100 
cells and counting labelled cells in a few such sized groups. 
Five categorizations were evaluated: (1) with the same per-
centages as for ER and PR—although this has no practi-
cal value, it makes the results directly comparable with the 
steroid hormone receptor values; (2) with cut-offs suggested 
by the 2009 St Gallen consensus (i.e., ≤ 15%, 16–30%, 
and > 30% for low, intermediate, and high proliferation)[9]; 
(3) with a cut-off suggested by the 2011 St Gallen consensus 
(i.e., ≤ 13% and > 13% for low and high proliferation) [10]; 
(4) with a cut-off suggested by the 2013 St Gallen consensus 
(i.e., ≤ 20% and > 20% for low and high proliferation) [11]; 
and finally (5) with cut-offs suggested by the 2015 St Gal-
len consensus (i.e., at least 10% less than the median label-
ling of ER+ breast cancers for low labelling, at least 10% 
more than this median value for high proliferation, and the 
range in between for intermediate labelling) [12]. For this, 
the median Ki67 labelling (15%) of ER+ cases diagnosed in 
2020 (n = 170) was used.
Rating reliability was analysed by the intraclass correla-
tion coefficient (two-way random effects, absolute agree-
ment, single rater/measurement; ICC (2, 1) [25]).
ONEST, as initially described by Reisenbichler et al. [24], 
was calculated for a randomly selected 100 permutations of 
the 362,880 (= 9!) possible permutations of ranked patholo-
gists. The Kruskal Wallis test was applied to characterize 
and compare minimum values (i.e., the lowest plot—the 
“worst performance”); p values < 0.05 were considered sta-
tistically significant. The calculations were performed with 
the Real Statistics Add-Ins of Excel [26]. Details of the 
ONEST calculation are provided in Supplementary Mate-
rial 1.
Since no patient data were used in this non-interven-
tional retrospective study, no ethical approval was deemed 
necessary.
Results
Nine pathologists, including 2 residents trained in breast 
pathology, have evaluated the 100 cases. They all had expe-
rience in the field of breast pathology, ranging from > 1 
to > 25 years.
As the consistency of classifying the cases is dependent 
on the percentage of cells staining, with 0% and 100% being 
the easiest to categorize unanimously, Supplementary Fig. 1 
demonstrates the boxplots for the main descriptive statisti-
cal features of the 50 CNB and 50 EXC specimens for the 3 
nuclear markers assessed. As the cases were continuous but 
with the exclusion of some ER- cases, the median scores for 
the markers are only characteristic for the cases assessed; but 
to some extent, they also reflect breast cancer cases encoun-
tered in routine practice. The median percentage (interquar-
tile range) of ER+ , PR+ , and Ki67+ cells as assessed by 
the 9 pathologists in biopsies vs excision specimens were 95 
(30) vs 95 (15) (ER), 60 (89) vs 73 (95) (PR), and 20 (85) 
vs 10 (20) (Ki67), respectively. These values highlight that 
most nuclei stained for ER, less nuclei labelled with PR, and 
the least with Ki67.
The OPAs per diagnostic category are displayed in 
Supplementary Tables 1 and 2. The 100% agreement per 
diagnostic category for ER and PR was high in both CNB 
and EXC specimens (38 to 47/50 cases) but was somewhat 
worse for a similar distribution of Ki67 (31/50) on CNB 
and less than 50% (22/50) for Ki67 on EXC (Supplemen-
tary Table 1). With different St Gallen recommendations 
on interpreting Ki67 labelling values, consensus on cat-
egorization was best on CNB with the 2011 two-tiered-
classification: 30/50 cases were classified with 100% 
agreement (Supplementary Table 2).
The ICC values for the evaluated parameters are shown 
in Table 1. According to these, most classifications relat-
ing to the ER and PR status of the tumours have an excel-
lent or good to excellent level of reliability. In contrast, 
all Ki67 related classifications have moderate or moderate 
to good reliability. The difference in ICC values of the 
3-category-based (1% and 10% cut-off) classification of 
ER or PR vs Ki67 is striking, whereas the difference in 
ICC values of different Ki67 categorization is less promi-
nent. No major or consistent differences are seen in the 
ICC values of CNB and EXC specimens.
As demonstrative examples, ONEST plots of the ER, 
PR, and Ki67 classifications of CNB samples reflected in 
Supplementary Table 1 (i.e., with categories < 1%, 1–10%, 
and > 10%) are shown in Fig. 1. The A1, B1, and C1 parts 
of the figure demonstrate OPACs of ER (A1), PR (B1), 
and Ki67 (C1) classifications of 100 randomly selected 
permutations of 9 pathologists, whereas only the minimum 
and maximum values of these OPA values are shown in 
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the A2, B2, and C2 parts. Rather than demonstrating all 
possible ONEST plots, the minimum, maximum, and mean 
OPA values are shown in Supplementary Table 3, and the 
differences between the maximum and minimum OPAs, 
the OPA for all 9 pathologists, and the number of patholo-
gists to reach the plateau are shown in Table 2.
As concerns the classifications according to the 1% and 
10% cut-offs or the different St Gallen criteria, the inten-
sity scores for ER and PR, and the Allred scores lumped 
into 4 categories, there were no significant differences 
(Kruskal–Wallis tests p > 0.05) between CNB and EXC sam-
ple OPAs for the PR intensity scores and the Ki67 categories 
according to St Gallen 2013 criteria; all the other classifi-
cations significantly differed in OPAs for CNB and EXC 
specimens. Agreement was better on CNB specimens for 
ER intensity, PR status, Ki67 categories with 1% and 10% 
cut-offs, St Gallen 2011 and 2015 cut-offs and was better on 
EXC specimens for ER status, ER and PR Allred scores, and 
Ki67 classification according to St Gallen 2009.
Using the < 1%, 1–10%, and > 10% cut-offs for catego-
rization, there were significant differences in the minimum 
(and average) OPA values from the ONEST plots between 
any pairs of ER, PR, and Ki67s both on CNB and EXC 
specimens.
The 4-category (0.2 vs 3–4, vs 5–6 vs 78) Allred score 
grouping minimum OPA values were also significantly dif-
ferent for ER and PR on both CNB and EXC specimens, 
whereas these values for the scores for average intensity of 
staining showed significant differences only for CNB speci-
mens and not for EXC specimens (p = 0.44).
As concerns the classification of Ki-67 labelling indices 
into low vs high (vs intermediate if defined) proliferation 
according to different definitions proposed by consecutive 
St Gallen consensus conferences, the highest rate of OPA 
was noted with the 2013 proposal, i.e., a classification based 
on ≤ 20% vs 20%, and this was significantly better than any 
other St Gallen recommendation–based segregation. How-
ever, ICC values still suggested a moderate to good (CNB) 
or good (EXC) level of reliability (Table 1).
As 9! (362,880) is still a manageable number, the mini-
mum values of OPAs from the 100 random permutations 
were compared with the minimum values of OPAs from all 
permutations (i.e., the lowest OPAC). No significant dif-
ferences were noted, most comparisons (Kruskal Wallis) 
yielded p = 1, and p values ranged from 0.64 to 1 (Fig. 2).
Discussion
It is recognized that many factors influence the assessment 
of ER, PR, and Ki67 by IHC. This study concentrated on 
interpretational issues only, although two different types 
of material were evaluated in parallel: in contrast to whole 
section excision material, core biopsies have better fixation 
parameters and a smaller overall area to evaluate, potentially 
diminishing the discrepancies between observers.
Table. 1  ICC (95% credible interval, CI) values for the investigated categories
CNB EXC
ER intensity 0,813 (0,740-0,876) 0,873 (0,815-0,919)
PR intensity 0,782 (0,705-0,851) 0,830 (0,765-0,886)
ER (QS) 0,924 (0,890-0,951) 0,979 (0,968-0,987)
PR (QS) 0,920 (0,886-0,948) 0,927 (0,896-0,953)
ER (%) 0,909 (0,870-0,941) 0,969 (0,954-0,981)
PR (%) 0,942 (0,917-0,941) 0,935 (0,907-0,958)
Ki67 (%) 0,874 (0,812-0,921) 0,812 (0,742-0,874)
ER (% - 3 categories) 0,918 (0,883-0,947) 0,996 (0,994-0,997)
PR (% - 3 categories) 0,946 (0,922-0,965) 0,918 (0,883-0,947)
Ki67 (% - 3 categories) 0,673 (0,576-0,768) 0,625 (0,520-0,731)
Ki67 (St Gallen-2009) 0,760 (0,677-0,836) 0,707 (0,614-0,796)
Ki67 (St Gallen-2011) 0,654 (0,555-0,753) 0,629 (0,525-0,735)
Ki67 (St Gallen-2013) 0,629 (0,526-0,733) 0,649 (0,546-0,751)
Ki67 (St Gallen-2015) 0,698 (0,600-0,790) 0,700 (0,603-0,791)
ER oestrogen receptor, PR progesterone receptor, QS quick score or Allred score; intensity refers to average intensity scorings; (%) refers to the 
recorded percentage values with all different values representing a different category, 3 categories refer to < 1%, 1–10%, and > 10% categoriza-
tion, St Gallen—year refers to the categories of low/(intermediate)/high Ki67 labelling as defined by the St Gallen Consensus Conference of the 
given year (see “Methods” section). The greyscale reflects the categorization of the level of reliability into excellent (ICC > 0.9), good to excel-
lent, good (ICC > 0.75–0.9), moderate to good and moderate (ICC > 0.5–0.75) from white to deeper shades of grey; the 95% CIs are taken into 
account for the categorization [25]
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With 100 cases mostly reflecting daily routine, ER and 
PR statuses (negative vs low positive vs positive) were the 
most reproducible with excellent or excellent to good clas-
sification of reliability (Tables 1 and 2). ONEST suggested 
that the categorization of ER showed the highest rates of 
OPA, and even 2 observers were sufficient to reflect repro-
ducibility of assessment of the ER status, whereas PR was 
characterized by slightly lower OPA values and by 3 observ-
ers required for reflecting reproducibility (Tables 1 and 2, 
Fig. 1). The results suggest that these tests are valuable as 
assessed in daily practice. Although no recommendation 
exists to use Ki67 with < 1%, 1–10%, and > 10% categories, 
to allow better comparison with the determination of ER 
and PR, the virtual exercise of classifying cases according 
to these cut-offs was also done: the ICC suggested moderate 
or moderate to good reproducibility, the OPAs per increas-
ing number of pathologists were lower, and the number of 
observers required for better assessment of reproducibility 
was 4 (Tables 1 and 2, Fig. 1). As all tests reflected the 
estimation of the percentage of stained tumour cell nuclei 
(without the influence of staining intensity) and their clas-
sification according to the same cut-off limits, the differ-
ence between the individual tests was only the proportion of 
stained nuclei and the size of the specimen (greater for EXC 
than CNB). It has been found in several studies that interme-
diate categories are less reproducible than categories at the 
extremes [23, 27, 28], and indeed, as indicated in the results 
(see also Supplementary Fig. 1), Ki67 staining proportions 
were often away from the extremes, which seems typical for 
this marker [29].
The intensity of staining was also assessed for ER and 
PR, and although the ICC values were reasonably good or 
even good to excellent (range 0.78–0.87), the ONEST analy-
sis suggested that OPA values were low (0.36 to 0.48), with 
less than half of the pathologist agreeing, and therefore, 4 
to 5 pathologists are needed to assess reproducibility. As the 
Allred quick scores are composed of subscores for intensity 
and for the proportion of stained cells, these consequently 
had ICC values reflecting excellent (with the 95% CI, good 
to excellent) reliability. However, the ONEST analysis of 
Allred scores reflected up to 22% difference between two 
observers, and 2 to 5 pathologists were required to assess 
reproducibility, with the worst results for PR assessment on 
CNBs (Table 2).
The comparison of ER, PR, and Ki67 with the 1% and 
10% cut-offs suggested that the last biomarker was the 
least reproducible, and this could probably be explained 
by the relatively wide range of the stained cells per case. 
On the basis of daily practices reflected in this study, dif-
ferent classifications of low vs high (vs intermediate when 
defined) proliferation categories are not excellently repro-
ducible (Table 1); the ICC values ranged from 0.63 to 0.76. 
Table. 2  Main results of the 






OPA with 9 
pathologists
ER categories (< 1%, 1–10%, > 10%) CNB 0.04 2 0.96
ER categories (< 1%, 1–10%, > 10%) EXC 0.02 2 0.98
ER intensity CNB 0.32 5 0.48
ER intensity EXC 0.36 4 0.38
ER Allred scores (0,2; 3–4; 5–6; 7–8) CNB 0.12 4 0.72
ER Allred scores (0,2; 3–4; 5–6; 7–8) EXC 0.10 2 0.90
PR categories (< 1%, 1–10%, > 10%) CNB 0.12 3 0.82
PR categories (< 1%, 1–10%, > 10%) EXC 0.18 3 0.76
PR intensity CNB 0.36 4 0.38
PR intensity EXC 0.42 4 0.36
PR Allred scores (0,2; 3–4; 5–6; 7–8) CNB 0.22 5 0.48
PR Allred scores (0,2; 3–4; 5–6; 7–8) EXC 0.20 3 0.58
Ki67 categories (< 1%, 1–10%, > 10%) CNB 0.18 4 0.62
Ki67 categories (< 1%, 1–10%, > 10%) EXC 0.26 4 0.44
Ki67 St Gallen 2009 CNB 0.30 4 0.32
Ki67 St Gallen 2009 EXC 0.28 4 0.38
Ki67 St Gallen 2011 CNB 0.18 5 0.6
Ki67 St Gallen 2011 EXC 0.24 4 0.5
Ki67 St Gallen 2013 CNB 0.22 5 0.52
Ki67 St Gallen 2013 EXC 0.26 5 0.54
Ki67 St Gallen 2015 CNB 0.3 4 0.32
Ki67 St Gallen 2015 EXC 0.34 5 0.26
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Interestingly, the best ICC value was that of a 3-tiered 
classification (St Gallen 2009) [9] for CNB specimens. 
In keeping with the lower ICC values for any Ki67 deter-
mination (than for ER or PR staining), the ONEST analy-
sis also suggested higher maximal differences between 
2 observers (up to 34%), lower OPAs with all observers 
(26% as a minimum), and higher number of pathologists 
required to reflect reproducibility (mostly 5). The two-
tiered systems of St Gallen recommendations from 2011 
[10] and 2013 [11] had better parameters (lower maximum 
differences between 2 observers and higher OPAs for all 
observers).
It is evident from improved ICC values reported by the 
International Ki67 Working Group that scoring consistency 
of Ki67 can also be improved by standardized reporting, 
even without image analysis [16], and standardization is the 
way forward to achieve reliable Ki67 assessments. However, 
this study was not devised to increase reproducibility, but 
reproducibility was described as basic data, and the analysis 
was complemented by the newly developed ONEST method, 
to see what this can add to studies of reproducibility in case 
of biomarkers deemed suitable for prognostic or predictive 
conclusions. As hypothesized, ONEST can complement 
conventional statistics of agreement. It can prove or simply 
visualize that a biomarker is reliable, due to its easy assess-
ment and natural distribution (like ER in our series; high 
plots with narrow bandwidth, Fig. 1A). It can also highlight 
weaknesses of biomarker assessment (high interrater dif-
ferences, i.e., wide band between the top and the bottom 
curves, and low OPA values with all observers included, 
Fig. 1). This is in addition to the original aim of ONEST to 
determine the number of observers needed for the plot to 
reach a kind of plateau, i.e., the number minimally required 
to reliably reflect reproducibility. In this context, the results 
of some earlier reports, including one of ours [28], may be 
challenged on the basis of the number of observers involved; 
in the referred study, only three observers were included 
for the categorization of Ki67 staining according to the St 
Gallen 2009 criteria, whereas the current ONEST analysis 
would suggest at least 4, for reliable estimations.
Our results may also have an influence on current prac-
tice. While the eyeballing assessment of ER and PR staining 
and the determination of the Allred quick scores seem reli-
able, the same type of evaluation of Ki67 staining does not. 
Lower ICC values and poorer ONEST profiles independ-
ent of the cut-off values used by different recommendations 
point to a greater need for a more standardized assessment of 
Ki67, as proposed by the International Ki67 Working Group 
[30].
In summary, we have applied ONEST for characteriz-
ing the reproducibility of three biomarkers, all evaluated by 
estimating the proportion of immunostained nuclei on CNB 
and EXC specimens. The differences in reproducibility were 
mainly explained by the distribution of the stained nuclei 
around or away from the extremes (0% and 100%). ONEST 
gave useful supplementary information and its plots helped 
in visualizing the results. The minimum OPA values, the 
2 3 4 5 6 7 8 9
MIN (100) 0.68 0.6 0.56 0.54 0.52 0.52 0.52 0.52
MAX (100) 0.9 0.82 0.78 0.7 0.66 0.62 0.58 0.52
AVE (100) 0.813 0.7152 0.6594 0.6172 0.5844 0.5632 0.5392 0.52
MIN (All) 0.68 0.58 0.54 0.52 0.52 0.52 0.52 0.52
MAX (All) 0.9 0.82 0.78 0.7 0.66 0.62 0.58 0.52










Fig. 2  Comparison of OPAs derived from 100 and all permutations 
of pathologists for Ki67 categorization according to St Gallen 2013 
recommendation. MIN: minimum, MAX: maximum, AVE: aver-
age, (100): for the 100 permutations, (All): for all 9! permutations. 
The MIN(All) and MAX(All) represent the worst and best OPAC, 
whereas the MIN(100) and MAX(100) curves lay on the worst and 
best OPA values and do not necessarily represent an OPAC. The AVE 
values are just derived from the 100 or 9! OPA values belonging to 
the number of pathologists on the x-axis. The MAX values (curves) 
overlap completely. The AVE curves virtually overlap completely and 
the MIN(100) vs MIN(All) curves deviate slightly, but the differences 
are not significant (p = 0.64; Kruskal Wallis)
 Virchows Archiv
1 3
greatest difference in OPA for 2 pathologists and the OPA 
for all pathologists, are all reflected in ONEST plots.
Supplementary Information The online version contains supplemen-
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